Integrating hypertension and HIV care in Namibia: A quality improvement collaborative approach

Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Hilaria Ashivudhi, Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu, Linea Hans, Gram Mutandi, Suzanne Jedd, Francina Tjituka, Ndapewa Hamunime, Bruce D. Agins

1 Ministry of Health and Social Services, Windhoek, Namibia, 2 Institute for Global Health Sciences, University of California, San Francisco, California, United States of America, 3 Harvard Medical School, Boston, Massachusetts, United States of America, 4 U.S. Centers for Disease Control and Prevention, Windhoek, Namibia, 5 Office of the U.S. Global AIDS Coordinator and Health Diplomacy, Pretoria, South Africa

*bruce.agins@ucsf.edu

Abstract

Background

Hypertension (HTN) is highly prevalent among people with HIV (PWH) in Namibia, but screening and treatment for HTN are not routinely offered as part of HIV care delivery. We report the implementation of a quality improvement collaborative (QIC) to accelerate integration of HTN and HIV care within public-sector health facilities in Namibia.

Methods

Twenty-four facilities participated in the QIC with the aim of increasing HTN screening and treatment among adult PWH (>15 years). HTN was defined according to national treatment guidelines (i.e., systolic blood pressure >140 and/or diastolic blood pressure >90 across three measurements and at least two occasions), and decisions regarding initiation of treatment were made by physicians only. Teams from participating hospitals used quality improvement methods, monthly measurement of performance indicators, and small-scale tests of change to implement contextually tailored interventions. Coaching of sites was performed on a monthly basis by clinical officers with expertise in QI and HIV, and sites were convened as part of learning sessions to facilitate diffusion of effective interventions.

Results

Between March 2017 and March 2018, hypertension screening occurred as part of 183,043 (86%) clinical encounters at participating facilities. Among 1,759 PWH newly diagnosed with HTN, 992 (56%) were initiated on first-line treatment. Rates of treatment initiation were higher in facilities with an on-site physician (61%) compared to those without one (51%).


Check for updates

OPEN ACCESS

Citation: Basenero A, Neidel J, Ikeda DJ, Ashivudhi H, Mpariwa S, Kamangu JWN, et al. (2022) Integrating hypertension and HIV care in Namibia: A quality improvement collaborative approach. PLoS ONE 17(8): e0272727. https://doi.org/10.1371/journal.pone.0272727

Editor: Thomas Tischer, PLOS: Public Library of Science, UNITED KINGDOM

Received: February 8, 2022

Accepted: July 25, 2022

Published: August 11, 2022

Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0272727

Copyright: © 2022 Basenero et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All relevant data are within the paper and its Supporting information files.
and treatment. Among barriers to implementation, teams pointed to malfunctions of blood pressure machines and stock outs of antihypertensive medications as common challenges.

Conclusions
Implementation of a QIC provided a structured approach for integrating HTN and HIV services across 24 high-volume facilities in Namibia. As rates of HTN treatment remained low despite ongoing facility-level changes, policy-level interventions—such as task sharing and supply chain strengthening—should be pursued to further improve delivery of HTN care among PWH beyond initial screening.

Introduction
The scale up of antiretroviral therapy (ART) in sub-Saharan Africa (SSA) has led to steep declines in HIV-related mortality. In Namibia, a sparsely populated, middle-income country in SSA where an estimated 12% of the adult population is living with HIV, deaths from HIV have fallen by 22% since 2010 [1]. Although communicable diseases, including HIV, still comprise the leading causes of morbidity and mortality in Namibia [2], the prevalence of non-communicable diseases (NCD) such as cardiovascular disease, diabetes, and cancer has risen sharply, contributing to nearly 41% of all yearly deaths. Among preventable risk factors for NCDs, elevated blood pressure (i.e., hypertension) has been identified as the greatest contributor to NCD-related death and disability in Namibia [3]. Hypertension (HTN) affects an estimated one in five adults in Namibia [4, 5], yet remains underdiagnosed and undertreated, with only 47% reporting awareness of their condition and less than 20% achieving adequate control [5]. This gap has particular relevance to the care of PWH, who bear a disproportionate burden of HTN [6], and whose risk of cardiovascular disease exceeds that of the general population by a factor of two [7].

Over the past two decades, primary healthcare systems in Namibia and other countries in SSA with high burdens of HIV have evolved to support the engagement of people with HIV (PWH) in life-long care [8]. As decentralized platforms of longitudinal service delivery, these systems are uniquely suited to provide integrated care for the growing number of PWH with HTN [9]. Indeed, a cohort study in South Africa has observed an “ART advantage,” showing that individuals engaged in HIV care were more likely to receive HTN screening and treatment than the general population [10]. Notably, integrated care has been previously implemented to address sexual and reproductive health in Namibia [11]. However, despite a clear opportunity for synergy and cost saving [12], implementation of integrated models of care for HIV and HTN in LMICs has been discouragingly slow. Several factors have been identified as barriers to implementation, including limited human resource capacity, fragile supply chains for diagnostic equipment and medication, weak health information systems, and ambiguous or nonexistent guidance on implementation [13]. In these settings, new interventions, models, and approaches to integrate HIV and HTN services at scale are needed, with specific attention to how context may influence their implementation and scalability [14–16].

Quality improvement collaboratives (QIC) have been promoted as an effective strategy for improving the quality of healthcare delivery across diverse contexts [17, 18]. Specifically, QICs seek to bridge the “know-do” gap—the gulf between clinical guidelines and their implementation—through capacity building, group problem-solving, shared leadership, and normative pressure [19]. In HIV service delivery [20], QICs have been implemented to address performance gaps in areas as varied as mother-to-child transmission [21, 22], provider-initiated
testing and counseling [23, 24], ART initiation [25], tuberculosis preventive therapy coverage [26], viral load monitoring [27], and stigma reduction [28]. However, no work to date has investigated how QICs may be applied to address gaps in scale up of integrated service delivery. In this work, we report the implementation of a QIC—the Namibia Project for Retention of Patients on ART (NAMPROPA)—whose objective was to improve uptake of HTN screening and treatment in routine HIV care in Namibia.

**Methods**

**Implementation context**

NAMPROPA was launched in November 2016 by Namibia’s Ministry of Health and Social Services (MHSS) with the aim of improving care engagement, viral monitoring, viral suppression, and HTN screening and treatment in 24 ART facilities across three regions with high burdens of HIV—Khomas, Ohangwena, and Zambezi (Table 1). These sites were purposively selected based on their high relative patient volumes. All participating facilities are publicly funded and provide health services free-of-charge to over 50,000 PWH—nearly one third of all PWH receiving ART in Namibia’s public sector. Although all facilities dispense ART on site, only a minority stock anti-HTN medications recommended as “first-line” by Namibia’s Standard Treatment Guidelines. All facilities have a nurse on site, but only 33% have an on-site physician. In line with MHSS’s approach to task sharing and decentralized HIV care delivery [29–31], facilities without an on-site physician remain in frequent contact with a regional medical officer. Importantly, nurses in Namibia can initiate ART in patients with a new HIV diagnosis, but only physicians can provide an initial prescription for anti-HTN therapy. Prior to the implementation of NAMPROPA, HTN screening and treatment were not routinely conducted as part of HIV service delivery in participating sites. Technical support for implementation of the QIC was provided by the University of California, San Francisco (UCSF), the Health Resources and Service Administration, and the U.S. Centers for Disease Control and Prevention.

**QIC approach**

The design of NAMPROPA was adapted from the Institute for Healthcare Improvement’s Breakthrough Series Model, an improvement science methodology in which participating sites

| Table 1. Site characteristics, by region. |
|------------------------------------------|
| **Khomas** | **Ohangwena** | **Zambezi** |
| Adult HIV prevalence (%) | 8.3% | 17.9% | 22.3% |
| Participating facilities, n | 7 | 10 | 7 |
| ART caseloads, n | | | |
| 0–999 | 1 | 5 | 6 |
| 1000–4999 | 5 | 4 | 1 |
| 5000+ | 1 | 1 | 0 |
| Number of HCWs, n | | | |
| 0–10 | 0 | 1 | 1 |
| 11–20 | 5 | 2 | 2 |
| >20 | 2 | 7 | 5 |
| On-site physician?, n | | | |
| Yes | 6 | 3 | 2 |
| No | 1 | 7 | 5 |

ART=antiretroviral therapy; HCW=healthcare worker.

https://doi.org/10.1371/journal.pone.0272727.t001
are convened to apply quality improvement (QI) methods (e.g., Plan-Do-Study-Act cycles, cascade analysis, process mapping, root cause analysis) to the identification and improvement of gaps in a specific area of healthcare delivery [32]. QICs are complex, quasi-experimental interventions that collect repeated cross-sectional data to track implementation success [19]. Fig 1 presents specific QIC activities. In contrast to traditional QI approaches in which projects are implemented and evaluated at individual sites over a period of months, QICs feature more frequent performance measurement and smaller-scale tests of changes, enabling sites to test multiple interventions and share experiences with other participating facilities over an accelerated period of time. The accumulation of evidence-informed [33] interventions and performance improvements are significantly accelerated through QICs, leading to the compilation of a "change package" for use in scale-up activities. Since an overarching aim of NAMPROPA was to promote QI capacity-building, no facilities were assigned to serve as controls. MHSS had significant prior experience implementing QI programming [34–36], but no QIC had been implemented in Namibia prior to NAMPROPA.

Coaching and support

Participating sites received coaching and support from regional and district clinical mentors, an existing cadre of physicians and nurses employed by MHSS with special expertise in HIV clinical care [29]. These mentors had been formally trained in QI principles, methods, and coaching through national MHSS-led QI seminars [34, 35]. As part of NAMPROPA activities, clinical mentors visited sites at a minimum of a monthly basis, integrating QI coaching into their routine activities to build capacity for HIV care and treatment with specific activities including review of sites’ performance data, communication of NAMPROPA updates, and assistance with design, execution, and evaluation of Plan-Do-Study-Act cycles. Between coaching visits, sites convened QI meetings to plan and track implementation. Technical support for regional mentors in QI methods and coaching was provided by MHSS and UCSF with monthly check-in calls to monitor implementation and discuss challenges.
Peer-to-peer exchange

Over 12 months, teams of three staff members from the 24 participating facilities, clinical mentors, and MHSS stakeholders were convened on three occasions as part of three-day, in-person learning sessions (LS). The objectives of LS were to gain proficiency in QI tools and methods, share examples of QI interventions, develop action plans, and prioritize future improvement activities. These LS also featured presentations from MHSS on current HTN treatment guidelines and protocols for referring patients with newly diagnosed HTN for treatment initiation. Between LS, ongoing peer-to-peer exchange was facilitated through participation in WhatsApp groups, email, and regional meetings.

Data collection

Rates of HTN screening and treatment were reported by participating sites to MHSS on a monthly basis using a pre-programmed electronic workbook (Microsoft Excel 2013, Microsoft Corporation, Redmond, WA) equipped to produce automated run charts. These data were subsequently aggregated to reflect collaborative-wide and region-specific performance and presented to sites for benchmarking. Measures were defined in alignment with Namibia’s Standard Treatment Guidelines for adults (>15 years) [37]. These guidelines define HTN as a blood pressure that consistently exceeds 140/90 mm Hg across three measurements and at least two occasions. In cases of mild HTN (<160/100 mm Hg), guidelines recommend provision of health education on mitigation of risk factors and monthly monitoring. Among patients with severe HTN (≥160/100 mm Hg) or mild HTN that is resistant to initial intervention, monotherapy with a thiazide diuretic (i.e., amiloride/hydrochlorothiazide) is recommended as first-line treatment. To capture “change ideas” and site-reported implementation barriers, we conducted semi-structured interviews of 138 health workers (i.e., physicians, nurses, pharmacists, data clerks, health assistants, and field officers) as part of site visits and undertook a content analysis of these interviews and facility presentations as part of LS. The number of coaching visits and QI meetings were tracked by MHSS on a monthly basis. As part of the QIC’s final learning session, participating facility teams compiled a “change package” of improvement interventions. During this process, participants from each region were convened to rank changes according to effectiveness (i.e., the magnitude of improvement on the basis of Plan-Do-Study-Act cycles) and perceived sustainability (i.e., how likely a change might be sustained in the long-term). Selected changes from each region were then presented to the large group, and a final list of changes was determined by group discussion and majority vote. Changes were subsequently collated according to domains of the Chronic Care Model—a heuristic for organizing changes that improve care for chronic conditions [38], including HIV [39].

Ethical considerations

Implementation of NAMPROPA activities, including data collection and analysis, was approved by MHSS and the institutional review board of UCSF, receiving a determination of non-research. As no patient-level data were collected, the need for informed consent was waived. We used SQUIRE (Standards for QUality Improvement Reporting Excellence) guidelines to structure reporting of NAMPROPA implementation and results [40].

Results

At baseline, no participating facilities were conducting screening for HTN. Prior to initiation of QIC activities, all sites were provided with blood pressure machines. Fig 2 reports the
number of monthly patient encounters during which HTN screening was provided. Of 213,714 clinical encounters at participating sites that occurred between March 2017 and March 2018, HTN screening was conducted as part of 183,043 (86%). Between LS 1 and 2, HTN screening occurred as a part of 80% of encounters, compared to 89% between LS 2 and 3. Barriers to HTN screening cited by facility teams included challenges recording and analyzing QIC measures; malfunctions of blood pressure machines; and difficulties following up with patients for multiple blood pressure readings.

Collection and reporting of data on HTN treatment did not begin until September 2017. Fig 3 displays the rate of treatment initiation among patients newly diagnosed with HTN each month. During the 7 months in which data on HTN treatment were collected, 1,759 patients on ART were newly diagnosed with HTN, and 992 (56%) were successfully initiated on treatment. Among sites with an on-site physician, treatment rates were 61%, compared to 51% among sites without an on-site physician. Several barriers to HTN treatment were noted by sites, including limited physician availability to initiate anti-HTN treatment; stock outs of medications; and difficulties tracking patient referrals to tertiary facilities for treatment initiation. Reassuringly, analyses of HIV-specific measures from NAMPROPA demonstrated no detrimental impact of HTN screening and treatment on care engagement, viral load monitoring or viral suppression [41].

During NAMPROPA, participating sites convened 204 QI meetings, and 100% received coaching visits at least monthly. As part of the QIC’s third and final learning session, participating facility teams compiled a “change package” of improvement interventions that were assessed, on the basis of findings from PDSA cycles, to be both effective and feasible to sustainably implement. During NAMPROPA implementation, fourteen interventions were adopted to address HTN screening and treatment. Table 2 presents these interventions by Chronic Care Model domain. Overall, interventions in the domains of delivery system design and
clinical information systems were most common, with sites implementing, respectively, four and three interventions in each of these domains.

**Discussion**

In this work, we have reported the implementation of a QIC to improve uptake of HTN screening and treatment as part of HIV care delivery. Over 12 months of implementation, HTN screening became routine in NAMPROPA sites, with coverage rates nearing 90% of all clinical encounters. Through these efforts, over 1,700 PWH were newly diagnosed with HTN, and nearly 1,000 were initiated on treatment. These results build on findings from previous work conducted in Ghana [42] and South Africa [25] that demonstrated the utility of a QIC approach in accelerating translation of clinical guidelines into practice. To our knowledge, the current work represents the first attempt to apply QIC methodology to the integration of HIV and HTN care in SSA.

Successful integration of services is a complex endeavor that requires extensive coordination, planning, and adaptation to local care contexts and resources constraints [43]. Among the challenges of integration lies the emergence of unintended, negative consequences, including increased clinic wait times [44, 45], stigma associated with care seeking for HIV and certain NCDs [46], and compromises to the effectiveness of care for existing disease-specific services. A notable strength of NAMPROPA was its concurrent collection, reporting, and continuous improvement of both HTN- and HIV-specific quality measures—a recommended approach for mitigating the impacts of unintended consequences in the context of scale up [47]. As Namibia’s national electronic health system for HIV care does not contain HTN-related fields, sites implemented several interventions to enable collection and management of HTN-specific data, including development of paper-based HTN registers and documentation.

Fig 3. HTN treatment rate and number of adult patients on ART newly diagnosed with HTN, September 2017–March 2018. ART–antiretroviral therapy; HTN–hypertension.

https://doi.org/10.1371/journal.pone.0272727.g003
Table 2. Implemented change ideas by Chronic Care Model domain.

| Chronic Care Model domain and definition | Intervention |
|----------------------------------------|--------------|
| Organization of health care            | • Involve clinic leadership in development and monitoring of QI interventions  
• Review monthly performance data in QIC indicators of HTN screening and treatment during QI team meetings on a weekly basis |
| Self-management support                 | • Include reminders in patient health passports to follow up for repeat BP screening if indicated |
| Community linkages                      | • Offer HTN screening during medication pick-ups at community-based ART delivery sites |
| Delivery system redesign                | • Nurses provide training to health assistants on use of automated BP machines and protocol for recording BP in registers  
• Re-design clinic flow to incorporate HTN screening as part of initial registration rather than during visit with nurse or physician  
• Streamline clinic flow to allow patients with need for follow-up BP reading, but no additional care, to present for screening rather than waiting in queue for nurse or physician  
• Stock anti-HTN medication in HIV clinic pharmacy to streamline medication pickups |
| Decision support                        | • Mentors provide refresher training to nurses on national guidelines for HTN treatment, including indication for counseling on behavior modification  
• Mentors provide refresher training on national guidelines for referring patients to outside facilities for HTN treatment initiation |
| Clinical information systems            | • Develop a blood pressure monitoring register with columns for medical record number, SBP, DBP, and whether patient is currently on HTN treatment  
• Record patients' BP readings in health passports and paper-based charts  
• Pharmacists and pharmacy assistants track stock outs of first-line anti-HTN medications  
• Include HTN screening data from community-based ART delivery sites in facilities' performance data |

ART—antiretroviral therapy; BP—blood pressure; DBP—diastolic blood pressure; HTN—hypertension; SBP—systolic blood pressure; QI—quality improvement; QIC—quality improvement collaborative.

https://doi.org/10.1371/journal.pone.0272727.t002

of blood pressure readings in patient health passports. These interventions, while effective in the short run of the QIC, have notable limitations compared to electronic systems. Apart from enabling QI activities [48] and improving supply chain management [49], an integrated health information system can promote continuity of care across facilities—a crucial, albeit underappreciated determinant of quality [50]. Further efforts to integrate HTN and HIV care may benefit from incorporation of HTN-related fields and pharmacy dispensing data into Namibia’s existing health information system.

As in other countries in SSA with shortages of healthcare workers, task sharing is essential to the success of HIV service delivery in Namibia [30]. However, in the absence of policies that enable task sharing for conditions beyond HIV, these shortages stand as a formidable hindrance to the scale up of integrated care in SSA [51]. In NAMPROPA, interventions to advance task sharing task sharing included capacity building of medical assistants to measure blood pressure and nurse-physician co-management of patients with an existing HTN diagnosis. Notably, however, while clinical guidelines in Namibia allow nurses to autonomously provide the full spectrum of HIV care, only physicians can initiate HTN treatment. Particularly in the two thirds of NAMPROPA sites without an on-site physician, PWH with a new diagnosis of HTN faced significant delays in treatment initiation, with many receiving referrals to other
facilities. Policy changes to enable nurse-led HTN treatment in SSA have been considered [51], and several pilot studies have explored the feasibility of nurse-led delivery models with encouraging results [52–55]. Should nurse-led models find broad acceptance, steady attention to quality of care remains paramount [51, 56]. A structured approach, such as a QIC, may be especially useful in these settings, not only as a way to monitor the quality of scale up, but additionally as a way to promote “communities of practice” [57] through capacity-building, mentorship, and peer learning. Like all complex interventions, however, QICs require evidence-informed adaptation to be successfully implemented in new settings [58]. As numerous factors—including leadership, staff readiness, patient volume, and provider workload—can influence implementation, attention to context is crucial, and insights from implementation science may be particularly useful as implementers seek to apply a QIC approach to integrated service delivery in other settings [59].

A key finding of NAMPROPA was the consistently low rates of linkage to HTN care, with monthly rates averaging less than 60%. Low rates of linkage to HTN treatment have been reported elsewhere [60], and underscore a need to support PWH along the full “cascade” of HTN care—from screening and diagnosis to treatment and adequate control [61]. Among system-level determinants of linkage, challenges with execution and documentation of referrals for HTN treatment were most prominent. Although sites have a standardized mechanism for placing referrals—and further streamlined this process as part of the QIC—many PWH with new HTN were nevertheless deterred by the prospect of travel to an outside facility, long wait times at outpatient departments, and stock outs of anti-HTN medications. Notably, control of HTN among those on treatment was not tracked as part of NAMPROPA, although a recent cross-sectional study from Namibia suggests an unmet need to improve engagement after linkage, finding that only 43% reported “acceptable” levels of adherence (i.e., ≥ 80%) [62]. Like HIV, delivery of effective HTN care requires attention to a full “cascade” of essential processes, from initial screening to long-term control [61]. With insights gained through NAMPROPA, system-level interventions such as supply chain strengthening, task shifting policy reform, differentiated care models, and community awareness campaigns, stand to further improve outcomes along the HTN treatment cascade.

Limitations
The present work has limitations. First, as data on HTN screening and treatment were not routinely collected prior to implementation of NAMPROPA, we were not able to estimate a precise baseline of performance from which to compare sites’ performance. Second, as the study did not include control facilities, we cannot assess the extent to which the Hawthorne effect may have contributed to observed improvements in participating facilities. Third, as sites were purposively selected, generalizability of selected interventions to other settings may be limited without further adaptation. Fourth, although the integration of HTN screening and treatment did not adversely affect clinical HIV outcomes, we were not able to assess the QIC’s effects on patient-centered outcomes such as satisfaction, wait times, and health literacy. Attention to these outcomes is an important consideration in efforts to scale up of integrated service delivery. Future work that incorporates insights from time-motion studies [44], patient-pathway analyses [63], and assessments of patient experience [64] should be pursued to better understand the effects of integration efforts on patient experience and care-seeking behaviors.

Conclusion
As the burden of HTN grows in SSA, new, large-scale approaches are needed to sustainably offer HTN screening and treatment to all PWH. In this work, we have reported the
implementation of a QIC to incorporate HTN screening and treatment into routine HIV care across 24-high volume facilities in Namibia. Bold policies and interventions to address system-level barriers such as brittle supply chains and limited human resources will be needed to ensure the success and sustainability of integrated service delivery in SSA. As linkage to initiation of HTN treatment remained a challenge despite focused QI activities, findings of this work suggest that the uptake of HTN screening and treatment is likely to benefit from further decentralization of integrated care.

Supporting information
S1 Data.
(XLSX)
S1 File.
(DOCX)

Acknowledgments
The authors thank QI teams from participating sites for their dedication to continuous improvement as part of NAMPROPA. The authors also acknowledge the support of Harold Phillips, Tracey Gantt, Katie O’Connor, Simon Agolory, Sodzi Sodzi-Tettey, and Ernest Kanyoke. Portions of data from this manuscript were previously presented as part of the 35th Conference of the International Society for Quality in Healthcare, September 23–26, 2018, Kuala Lumpur, Malaysia.

Author Contributions
Conceptualization: Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Bruce D. Agins.
Data curation: Apollo Basenero, Julie Neidel, Daniel J. Ikeda.
Formal analysis: Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Bruce D. Agins.
Funding acquisition: Bruce D. Agins.
Investigation: Apollo Basenero, Julie Neidel, Hilaria Ashivudhi, Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu, Bruce D. Agins.
Methodology: Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu, Linea Hans, Gram Mutandi, Francina Tjituka, Ndapewa Hamunime, Bruce D. Agins.
Project administration: Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu, Linea Hans, Gram Mutandi, Francina Tjituka, Ndapewa Hamunime, Bruce D. Agins.
Supervision: Apollo Basenero, Julie Neidel, Hilaria Ashivudhi, Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu, Linea Hans, Gram Mutandi, Francina Tjituka, Ndapewa Hamunime, Bruce D. Agins.
Validation: Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu.
Visualization: Daniel J. Ikeda.
Writing – original draft: Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Bruce D. Agins.
Writing – review & editing: Apollo Basenero, Julie Neidel, Daniel J. Ikeda, Hilaria Ashivudhi, Simbarashe Mpariwa, Jacques W. N. Kamangu, Mireille A. Mpalang Kakubu, Linea Hans, Gram Mutandi, Suzanne Jed, Francina Tjituka, Ndapewa Hamunime, Bruce D. Agins.
References

1. UNAIDS. UNAIDS data 2020. 2020. https://www.unaids.org/en/resources/documents/2020/unaids-data
2. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1204–1222. https://doi.org/10.1016/S0140-6736(20)30925-9 PMID: 33069326
3. GBD 2019 Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020; 396: 1223–1249. https://doi.org/10.1016/S0140-6736(20)30752-2 PMID: 33069327
4. Egede LE, Walker RJ, Monroe P, Williams JS, Campbell JA, Dawson AZ. HIV and cardiovascular disease in sub-Saharan Africa: Demographic and Health Survey data for 4 countries. BMC Public Health. 2021; 21: 1122. https://doi.org/10.1186/s12889-021-11218-5 PMID: 34118912
5. Craig LS, Gage AJ, Thomas AM. Prevalence and predictors of hypertension in Namibia: A national-level cross-sectional study. PLoS ONE. 2018; 13: e0204344. https://doi.org/10.1371/journal.pone.0204344 PMID: 30235324
6. Fahme SA, Bloomfield GS, Peck R. Hypertension in HIV-Infected Adults: Novel Pathophysiologic Mechanisms. Hypertension. 2018; 72: 44–55. https://doi.org/10.1161/HYPERTENSIONAHA.118.10893 PMID: 29776899
7. Shah ASV, Stelzle D, Lee KK, Beck EJ, Alam S, Clifford S, et al. Global Burden of Atherosclerotic Cardiovascular Disease in People Living With HIV: Systematic Review and Meta-Analysis. Circulation. 2018; 138: 1100–1112. https://doi.org/10.1161/CIRCULATIONAHA.117.033669 PMID: 29967196
8. Bekker L-G, Alleyne G, Baral S, Cepeda J, Daskalakis D, Dowdy D, et al. Advancing global health and strengthening the HIV response in the era of the Sustainable Development Goals: the International AIDS Society-Lancet Commission. Lancet. 2018; 392: 312–358. https://doi.org/10.1016/S0140-6736(18)31070-5 PMID: 30032975
9. Duffy M, Ojikutu B, Andrian S, Sohn E, Minor T, Hirschhorn LR. Non-communicable diseases and HIV care and treatment: models of integrated service delivery. Trop Med Int Health. 2017; 22: 926–937. https://doi.org/10.1111/tmi.12901 PMID: 28970759
10. Manne-Goehler J, Montana L, Gómez-Olivé FX, Rohr J, Harling G, Wagner RG, et al. The ART Advantage: Health Care Utilization for Diabetes and Hypertension in Rural South Africa. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2017; 75: S93–S105. https://doi.org/10.1097/QAD.0000000000001897 PMID: 29952795
11. Zapata T, Forster N, Campuzano P, Kambapani R, Brahmbhatt H, Hidinua G, et al. How to Integrate HIV and Sexual and Reproductive Health Services in Namibia, the Epako Clinic Case Study. Int J Integr Care. 2017; 17: 1. https://doi.org/10.5334/ijic.2489 PMID: 29776899
12. Bulstra CA, Hontelez JAC, Otto M, Stepanova A, Lamontagne E, Yakusik A, et al. Integrating HIV services and other health services: A systematic review and meta-analysis. PLoS Med. 2021; 18: e1003836. https://doi.org/10.1371/journal.pmed.1003836 PMID: 34752477
13. Topp SM, Abimbola S, Joshi R, Negin J. How to assess and prepare health systems in low- and middle-income countries for integration of services—a systematic review. Health Policy Plan. 2018; 33: 298–312. https://doi.org/10.1093/heapol/czx169 PMID: 29272396
14. Kemp CG, Weiner BJ, Sherr KH, Kupfer LE, Cherutich PK, Wilson D, et al. Implementation science for integration of HIV and non-communicable disease services in sub-Saharan Africa: a systematic review. AIDS. 2018; 32 Suppl 1: S93–S105. https://doi.org/10.1097/QAD.0000000000001897 PMID: 29952795
15. Edwards N, Barker PM. The importance of context in implementation research. J Acquir Immune Defic Syndr. 2014; 67 Suppl 2: S157–162. https://doi.org/10.1097/QAD.0000000000000322 PMID: 25310123
16. Ovretveit J, Dolan-Branton L, Marx M, Reid A, Reed J, Agins B. Adapting improvements to context: when, why and how? Int J Qual Health Care. 2018; 30: 20–23. https://doi.org/10.1093/intqhc/mzy013 PMID: 29878138
17. Garcia-Elorrio E, Rowe SY, Teijeiro ME, Ciapponi A, Rowe AK. The effectiveness of the quality improvement collaborative strategy in low- and middle-income countries: A systematic review and meta-analysis. PLoS ONE. 2019; 14: e0221910. https://doi.org/10.1371/journal.pone.0221910 PMID: 31581197
18. Wells S, Tamir O, Gray J, Naidoo D, Bekhit M, Goldmann D. Are quality improvement collaboratives effective? A systematic review. BMJ Qual Saf. 2018; 27: 226–240. https://doi.org/10.1136/bmjqs-2017-006926 PMID: 29055899
19. Zamboni K, Baker U, Tyagi M, Schellenberg J, Hill Z, Hanson C. How and under what circumstances do quality improvement collaboratives lead to better outcomes? A systematic review. Implement Sci. 2020; 15: 27. https://doi.org/10.1186/s13012-020-0978-z PMID: 32366289
20. Hargreaves S, Rustage K, Nellums LB, Bardfield JE, Agins B, Barker P, et al. Do Quality Improvement Initiatives Improve Outcomes for Patients in Antiretroviral Programs in Low- and Middle-Income Countries? A Systematic Review. J Acquir Immune Defic Syndr. 2018; 81: 487–496. https://doi.org/10.1097/QAI.0000000000002085 PMID: 31149954

21. Barker P, Quick T, Agins B, Rollins N, Sint TT, Stern AF. A 6-Country Collaborative Quality Improvement Initiative to Improve Nutrition and Decrease Mother-to-Child Transmission of HIV in Mother-Infant Pairs. J Int Assoc Provid AIDS Care. 2019; 18: 2325958219855625. https://doi.org/10.1177/2325958219855625 PMID: 31242800

22. Youngleson MS, Nikurunziza P, Jennings K, Arendse J, Mate KS, Barker P. Improving a mother to child HIV transmission programme through health system redesign: quality improvement, protocol adjustment and resource addition. PLoS ONE. 2010; 5: e13891. https://doi.org/10.1371/journal.pone.0013891 PMID: 21085479

23. Dougherty G, Panya M, Madevu-Matson C, Anyalechi GE, Clarke K, Fayorsey R, et al. Reaching the First 90: Improving Inpatient Pediatric Provider-Initiated HIV Testing and Counseling Using a Quality Improvement Collaborative Strategy in Tanzania. J Assoc Nurses AIDS Care. 2019. https://doi.org/10.1097/JUNC.0000000000000668 PMID: 30817370

24. Kassa G, Dougherty G, Madevu-Matson C, Egessimba G, Sartie K, Akinjeji A, et al. Improving inpatient provider-initiated HIV testing and counseling in Sierra Leone. PLoS ONE. 2020; 15: e0238358. https://doi.org/10.1371/journal.pone.0238358 PMID: 27068110

25. Webster PD, Sibanyoni M, Malekutu D, Mate KS, Venter WDF, Barker PM, et al. Using quality improvement to accelerate highly active antiretroviral treatment coverage in South Africa. BMJ Qual Saf. 2012; 21: 315–324. https://doi.org/10.1136/bmjqs-2011-000381 PMID: 22438327

26. Gengiah S, Barker PM, Yende-Zuma N, Mbatha M, Naidoo S, Taylor M, et al. A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcare clinics in South Africa. J Int AIDS Soc. 2021; 24: e25503. https://doi.org/10.1002/jia2.25503 PMID: 34498370

27. Rabkin M, Achwoka D, Akoth S, Boccanegra R, Kimani M, Leting I, et al. Improving Utilization of HIV Viral Load Test Results Using a Quality Improvement Collaborative in Western Kenya. J Assoc Nurses AIDS Care. 2020. https://doi.org/10.1097/JNC.0000000000001587 PMID: 31985509

28. Ikeda DJ, Nyblade L, Srinavaniviboonchai K, Agins BD. A quality improvement approach to the reduction of HIV-related stigma and discrimination in healthcare settings. BMJ Glob Health. 2019; 4: e001587. https://doi.org/10.1136/bmjgh-2019-001587 PMID: 31297246

29. Bikinesi L, O’Bryan G, Roscoe C, Mekonen T, Shoopala N, Mengisti A, et al. Implementation and evaluation of a Project ECHO telementoring program for the Namibian HIV workforce, Hum Resour Health. 2020; 18: 61. https://doi.org/10.1186/s12960-020-00503-w PMID: 32873303

30. O’Malley G, Asrat L, Sharma A, Hamunime N, Stephanus Y, Brandt L, et al. Nurse task shifting for antiretroviral treatment services in Namibia: implementation research to move evidence into action. PLoS One. 2014; 9: e92014. https://doi.org/10.1371/journal.pone.0092014 PMID: 24642894

31. Katirayi L, Shoopala N, Mitraka K, Mengistu A, Woelk G, Baughman AL, et al. Taking care to the patients: a qualitative evaluation of a community-based ART care program in northern Namibia. BMC Health Serv Res. 2022; 22: 498. https://doi.org/10.1186/s12913-022-07928-0 PMID: 35422033

32. Kilo CM. A framework for collaborative improvement: lessons from the Institute for Healthcare Improvement’s Breakthrough Series. Qual Manag Health Care. 1998; 6: 1–13. https://doi.org/10.1097/00019514-199806040-00001 PMID: 10339040

33. Psihopaidas D, Cohen SM, West T, Avery L, Dempsey A, Brown K, et al. Implementation science and the Health Resources and Services Administration’s Ryan White HIV/AIDS Program’s work towards ending the HIV epidemic in the United States. PLoS Med. 2020; 17: e1003128. https://doi.org/10.1371/journal.pmed.1003128 PMID: 31356852

34. Bardfield J, Agins B, Akiyama M, Basenero A, Lumphala P, Kainjjee-Tjituka F, et al. A quality improvement approach to capacity building in low- and middle-income countries. AIDS. 2015; 29 Suppl 2: S179–186. https://doi.org/10.1097/QAD.0000000000000719 PMID: 26102629

35. Basenero A, Gordon C, Hamunime N, Bardfield J, Agins B. A public health approach to quality management: how a disease-specific improvement program propelled a national health-systems-wide quality program in Namibia. 1st ed. Health Systems Improvement Across the Globe: Success Stories from 60 Countries. 1st ed. CRC Press; 2017. pp. 81–89.

36. Ikeda DJ, Basenero A, Murungu J, Jasmin M, Inimah M, Agins BD. Implementing quality improvement in tuberculosis programming: Lessons learned from the global HIV response. Journal of Clinical Tuberculosis and Other Mycobacterial Diseases. 2019; 17: 100116. https://doi.org/10.1016/j.jctube.2019.100116 PMID: 31788558

37. Ministry of Health and Social Services. Namibia Standard Treatment Guidelines. 2011.
38. Wagner EH, Glasgow RE, Davis C, Bonomi AE, Provost L, McCulloch D, et al. Quality improvement in chronic illness care: a collaborative approach. Jt Comm J Qual Improv. 2001; 27: 63–80. https://doi.org/10.1016/s1070-3241(01)27007-2 PMID: 11221012

39. Ikeda DJ, Hollander L, Weig S, Sawicki SV, Belanger DR, West NY, et al. The Facility-Level HIV Treatment Cascade: Using a Population Health Tool in Health Care Facilities to End the Epidemic in New York State. Open Forum Infect Dis. 2018; 5: ofy254. https://doi.org/10.1093/ofid/ofy254 PMID: 30386808

40. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016; 25: 986–992. https://doi.org/10.1136/bmjqs-2015-004411 PMID: 26369893

41. Palma AM, Rabkin M, Simelane S, Gachuhi AB, McNairy ML, Nuwagaba-Biribonwoh A, et al. A time-motion study of cardiovascular disease risk factor screening integrated into HIV clinic visits in Swaziland. J Int AIDS Soc. 2018; 21: e25099. https://doi.org/10.1017/jia2.25099 PMID: 29577617

42. Agins B, Basenero A, Khabo B, Neidell J, Mutandi G, Murungu J, et al. Improvement collaboratives led by ministries of health to achieve global 90-90-90 targets. 22nd International AIDS Conference. Amsterdam, Netherlands; 2018.

43. Agins B, Basenero A, Khabo B, Neidell J, Mutandi G, Murungu J, et al. Improvement collaboratives led by ministries of health to achieve global 90-90-90 targets. 22nd International AIDS Conference. Amsterdam, Netherlands; 2018.

44. Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA. HIV, Tuberculosis, and Noncommunicable Diseases: What Is Known About the Costs, Effects, and Cost-effectiveness of Integrated Care? J Acquir Immune Defic Syndr. 2014; 67: S87–S95. https://doi.org/10.1097/QAI.0000000000000254 PMID: 25117965

45. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044

46. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044

47. Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA. HIV, Tuberculosis, and Noncommunicable Diseases: What Is Known About the Costs, Effects, and Cost-effectiveness of Integrated Care? J Acquir Immune Defic Syndr. 2014; 67: S87–S95. https://doi.org/10.1097/QAI.0000000000000254 PMID: 25117965

48. Ogrinc G, Davies L, Goodman D, Batalden P, Davidoff F, Stevens D. SQUIRE 2.0 (Standards for Quality Improvement Reporting Excellence): revised publication guidelines from a detailed consensus process. BMJ Qual Saf. 2016; 25: 986–992. https://doi.org/10.1136/bmjqs-2015-004411 PMID: 26369893

49. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044

50. Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA. HIV, Tuberculosis, and Noncommunicable Diseases: What Is Known About the Costs, Effects, and Cost-effectiveness of Integrated Care? J Acquir Immune Defic Syndr. 2014; 67: S87–S95. https://doi.org/10.1097/QAI.0000000000000254 PMID: 25117965

51. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044

52. Hyle EP, Naidoo K, Su AE, El-Sadr WM, Freedberg KA. HIV, Tuberculosis, and Noncommunicable Diseases: What Is Known About the Costs, Effects, and Cost-effectiveness of Integrated Care? J Acquir Immune Defic Syndr. 2014; 67: S87–S95. https://doi.org/10.1097/QAI.0000000000000254 PMID: 25117965

53. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044

54. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044

55. Stockton MA, Giger K, Nyblade L. Scoping review of the role of HIV-related stigma and discrimination in noncommunicable disease care. PLoS ONE. 2018; 13: e0199602. https://doi.org/10.1371/journal.pone.0199602 PMID: 29928044
56. Anand TN, Joseph LM, Geetha AV, Prabhakaran D, Jeemon P. Task sharing with non-physician health-care workers for management of blood pressure in low-income and middle-income countries: a systematic review and meta-analysis. Lancet Glob Health. 2019; 7: e761–e771. https://doi.org/10.1016/S2214-109X(19)30077-4 PMID: 31097278

57. Wenger E, Snyder WM. Communities of practice: the organisational frontier. Harvard Business Review. 2000; 78: 139–145.

58. Barker PM, Reid A, Schall MW. A framework for scaling up health interventions: lessons from large-scale improvement initiatives in Africa. Implement Sci. 2016; 11: 12. https://doi.org/10.1186/s13012-016-0374-x PMID: 26821910

59. Geng EH, Nash D, Phanuphak N, Green K, Solomon S, Grimsrud A, et al. The question of the question: impactful implementation science to address the HIV epidemic. J Int AIDS Soc. 2022; 25: e25898. https://doi.org/10.1002/jia2.25898 PMID: 35384312

60. Heller DJ, Balzer LB, Kazi D, Charlebois ED, Kwarisima D, Mwangwa F, et al. Hypertension testing and treatment in Uganda and Kenya through the SEARCH study: An implementation fidelity and outcome evaluation. PLoS ONE. 2020; 15: e0222801. https://doi.org/10.1371/journal.pone.0222801 PMID: 31940346

61. Muddu M, Tusubira AK, Sharma SK, Akiteng AR, Ssinabulya I, Schwartz JI. Integrated Hypertension and HIV Care Cascades in an HIV Treatment Program in Eastern Uganda: A Retrospective Cohort Study. J Acquir Immune Defic Syndr. 2019; 81: 552–561. https://doi.org/10.1097/QAI.0000000000002067 PMID: 31045649

62. Nashilongo MM, Singu B, Kalemeera F, Mubita M, Naikaku E, Baker A, et al. Assessing Adherence to Antihypertensive Therapy in Primary Health Care in Namibia: Findings and Implications. Cardiovasc Drugs Ther. 2017; 31: 565–578. https://doi.org/10.1007/s10557-017-7656-8 PMID: 29032396

63. Brathwaite R, Hutchinson E, McKee M, Palafoux B, Balabanova D. The Long and Winding Road: A Systematic Literature Review Conceptualising Pathways for Hypertension Care and Control in Low- and Middle-Income Countries. Int J Health Policy Manag. 2020. https://doi.org/10.34172/ijhpm.2020.105 PMID: 32702800

64. Hing M, Hoffman RM, Seleman J, Chibwana F, Kahn D, Moucheraud C. "Blood pressure can kill you tomorrow, but HIV gives you time": illness perceptions and treatment experiences among Malawian individuals living with HIV and hypertension. Health Policy Plan. 2019; 34: ii36–ii44. https://doi.org/10.1093/heapol/czz112 PMID: 31723966